We recently performed a systematic review and meta‐analysis of the metabolic consequences of melatonin treatment in healthy individuals and patients with metabolic diseases and found no effects of treatment on fasting plasma glucose, but reduced fasting insulin levels and a tendency towards increased insulin sensitivity measured by homeostatic model assessment for insulin resistance (HOMA‐IR).16 This evidence concerns the gene INS and Other metabolic disease.